BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167:45-67. [PMID: 30974127 DOI: 10.1016/j.antiviral.2019.04.006] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 26.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhao B, Yang TF, Zheng R. Theory and reality of antivirals against SARS-CoV-2. World J Clin Cases 2021; 9(23): 6663-6673 [PMID: 34447813 DOI: 10.12998/wjcc.v9.i23.6663] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020;215:108448. [PMID: 32353634 DOI: 10.1016/j.clim.2020.108448] [Cited by in Crossref: 254] [Cited by in F6Publishing: 222] [Article Influence: 127.0] [Reference Citation Analysis]
3 Bolarin JA, Oluwatoyosi MA, Orege JI, Ayeni EA, Ibrahim YA, Adeyemi SB, Tiamiyu BB, Gbadegesin LA, Akinyemi TO, Odoh CK, Umeobi HI, Adeoye AB. Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. Int Immunopharmacol 2021;90:107228. [PMID: 33302035 DOI: 10.1016/j.intimp.2020.107228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Li L, Li R, Wu Z, Yang X, Zhao M, Liu J, Chen D. Therapeutic strategies for critically ill patients with COVID-19. Ann Intensive Care 2020;10:45. [PMID: 32307593 DOI: 10.1186/s13613-020-00661-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 27.0] [Reference Citation Analysis]
5 Notton T, Glazier JJ, Saykally VR, Thompson CE, Weinberger LS. RanDeL-Seq: a High-Throughput Method to Map Viral cis- and trans-Acting Elements. mBio 2021;12:e01724-20. [PMID: 33468683 DOI: 10.1128/mBio.01724-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yoshida I, Arikawa K, Honma Y, Inatani S, Yoshinaga M, Sugiyama H. Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants. Antimicrob Agents Chemother 2020;65:e01407-20. [PMID: 33046486 DOI: 10.1128/AAC.01407-20] [Reference Citation Analysis]
7 Goodarzi P, Mahdavi F, Mirzaei R, Hasanvand H, Sholeh M, Zamani F, Sohrabi M, Tabibzadeh A, Jeda AS, Niya MHK, Keyvani H, Karampoor S. Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. Int Immunopharmacol 2020;88:106885. [PMID: 32795893 DOI: 10.1016/j.intimp.2020.106885] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
8 Shahzad S, Willcox M. Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll. Med Hypotheses 2020;143:110080. [PMID: 32683221 DOI: 10.1016/j.mehy.2020.110080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Pothuri B, Alvarez Secord A, Armstrong DK, Chan J, Fader AN, Huh W, Kesterson J, Liu JF, Moore K, Westin SN, Naumann RW. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol 2020;158:16-24. [PMID: 32386911 DOI: 10.1016/j.ygyno.2020.04.694] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
10 Sedeyn K, Saelens X. New antibody-based prevention and treatment options for influenza. Antiviral Res 2019;170:104562. [PMID: 31323236 DOI: 10.1016/j.antiviral.2019.104562] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
11 Zhao X, Jiang Y, Zhao Y, Xi H, Liu C, Qu F, Feng X. Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening. Eur J Clin Microbiol Infect Dis 2020;39:1209-20. [PMID: 32328850 DOI: 10.1007/s10096-020-03897-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 24.5] [Reference Citation Analysis]
12 Martinez MA. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrob Agents Chemother 2020;64:e00399-20. [PMID: 32152082 DOI: 10.1128/AAC.00399-20] [Cited by in Crossref: 199] [Cited by in F6Publishing: 154] [Article Influence: 99.5] [Reference Citation Analysis]
13 Löwensteyn YN, Bont LJ. Clinical Development of Respiratory Syncytial Virus Antivirals-What We Can Learn From Oseltamivir. Clin Infect Dis 2020;71:2796-8. [PMID: 31915814 DOI: 10.1093/cid/ciz1169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Beigel JH, Aga E, Elie-Turenne MC, Cho J, Tebas P, Clark CL, Metcalf JP, Ozment C, Raviprakash K, Beeler J, Holley HP Jr, Warner S, Chorley C, Lane HC, Hughes MD, Davey RT Jr; IRC005 Study Team. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med 2019;7:941-50. [PMID: 31582360 DOI: 10.1016/S2213-2600(19)30199-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 31] [Article Influence: 18.0] [Reference Citation Analysis]
15 Esposito S, Bianchini S, Argentiero A, Neglia C, Principi N. How does one choose the appropriate pharmacotherapy for children with lower respiratory tract infections? Expert Opin Pharmacother 2020;21:1739-47. [PMID: 32567405 DOI: 10.1080/14656566.2020.1781091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Mehmood I, Ijaz M, Ahmad S, Ahmed T, Bari A, Abro A, Allemailem KS, Almatroudi A, Tahir Ul Qamar M. SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development. Int J Environ Res Public Health 2021;18:1626. [PMID: 33567746 DOI: 10.3390/ijerph18041626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Vendeville S, Tahri A, Hu L, Demin S, Cooymans L, Vos A, Kwanten L, Van den Berg J, Battles MB, Mclellan JS, Koul A, Raboisson P, Roymans D, Jonckers THM. Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1 H -indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2 H -imidazo[4,5- c ]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus. J Med Chem 2020;63:8046-58. [DOI: 10.1021/acs.jmedchem.0c00226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Masterson CH, Ceccato A, Artigas A, Dos Santos C, Rocco PR, Rolandsson Enes S, Weiss DJ, McAuley D, Matthay MA, English K, Curley GF, Laffey JG. Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges. Intensive Care Med Exp 2021;9:61. [PMID: 34970706 DOI: 10.1186/s40635-021-00424-5] [Reference Citation Analysis]
19 Levine CB, Vasistha S, Persson CC, Larson LR, Kratochvil CJ, Mehta AK, Hicks LJ, Lowe AE, Kortepeter MG, Sauer LM. Prepared to Act: Lessons Learned by the Special Pathogens Research Network, Based on Collaborations with the NIAID-Led Adaptive COVID-19 Treatment Trial. Health Secur 2022. [PMID: 35483093 DOI: 10.1089/hs.2021.0178] [Reference Citation Analysis]
20 Maheden K, Todd B, Gordon CJ, Tchesnokov EP, Götte M. Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. Enzymes 2021;49:315-54. [PMID: 34696837 DOI: 10.1016/bs.enz.2021.07.002] [Reference Citation Analysis]
21 Martinez MA. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus. Antimicrob Agents Chemother 2020;64:e00399-20. [PMID: 32152082 DOI: 10.1128/AAC.00399-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 de Almeida SMV, Santos Soares JC, Dos Santos KL, Alves JEF, Ribeiro AG, Jacob ÍTT, da Silva Ferreira CJ, Dos Santos JC, de Oliveira JF, de Carvalho Junior LB, de Lima MDCA. COVID-19 therapy: What weapons do we bring into battle? Bioorg Med Chem 2020;28:115757. [PMID: 32992245 DOI: 10.1016/j.bmc.2020.115757] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
23 Cichero E, Calautti A, Francesconi V, Tonelli M, Schenone S, Fossa P. Probing In Silico the Benzimidazole Privileged Scaffold for the Development of Drug-like Anti-RSV Agents. Pharmaceuticals (Basel) 2021;14:1307. [PMID: 34959708 DOI: 10.3390/ph14121307] [Reference Citation Analysis]
24 Jabeen M, Dutot M, Fagon R, Verrier B, Monge C. Seaweed Sulfated Polysaccharides against Respiratory Viral Infections. Pharmaceutics 2021;13:733. [PMID: 34065660 DOI: 10.3390/pharmaceutics13050733] [Reference Citation Analysis]
25 Beigel JH, Hayden FG. Influenza Therapeutics in Clinical Practice-Challenges and Recent Advances. Cold Spring Harb Perspect Med 2021;11:a038463. [PMID: 32041763 DOI: 10.1101/cshperspect.a038463] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
26 Li H, Xue Q, Xu X. Involvement of the Nervous System in SARS-CoV-2 Infection. Neurotox Res 2020;38:1-7. [PMID: 32399719 DOI: 10.1007/s12640-020-00219-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 24.5] [Reference Citation Analysis]
27 Rahman F, Libre C, Oleinikov A, Tcherniuk S. Chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A. J Gen Virol 2021;102. [PMID: 34342560 DOI: 10.1099/jgv.0.001627] [Reference Citation Analysis]
28 Fang Q, Wang D. Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir. Biosafety and Health 2020;2:64-70. [DOI: 10.1016/j.bsheal.2020.04.004] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Favilli A, Mattei Gentili M, Raspa F, Giardina I, Parazzini F, Vitagliano A, Borisova AV, Gerli S. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. J Matern Fetal Neonatal Med 2020;:1-14. [PMID: 32508168 DOI: 10.1080/14767058.2020.1774875] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
30 Mammas IN, Drysdale SB, Rath B, Theodoridou M, Papaioannou G, Papatheodoropoulou A, Koutsounaki E, Koutsaftiki C, Kozanidou E, Achtsidis V, Korovessi P, Chrousos GP, Spandidos DA. Update on current views and advances on RSV infection (Review). Int J Mol Med 2020;46:509-20. [PMID: 32626981 DOI: 10.3892/ijmm.2020.4641] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
31 Sahu T, Verma HK, Bhaskar LVKS. Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required. World J Virol 2022; 11(2): 107-110 [DOI: 10.5501/wjv.v11.i2.107] [Reference Citation Analysis]
32 Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen KY. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695-1704. [PMID: 32401715 DOI: 10.1016/s0140-6736(20)31042-4] [Cited by in Crossref: 718] [Cited by in F6Publishing: 485] [Article Influence: 359.0] [Reference Citation Analysis]
33 Mishra AR, Rani P, Krishankumar R, Ravichandran KS, Kar S. An extended fuzzy decision-making framework using hesitant fuzzy sets for the drug selection to treat the mild symptoms of Coronavirus Disease 2019 (COVID-19). Appl Soft Comput 2021;103:107155. [PMID: 33568967 DOI: 10.1016/j.asoc.2021.107155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
34 Choudhury A, Das NC, Patra R, Bhattacharya M, Ghosh P, Patra BC, Mukherjee S. Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach. Future Virology 2021;16:277-91. [DOI: 10.2217/fvl-2020-0342] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
35 Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81:537-540. [PMID: 32129518 DOI: 10.1002/ddr.21656] [Cited by in Crossref: 417] [Cited by in F6Publishing: 414] [Article Influence: 208.5] [Reference Citation Analysis]
36 Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020;395:e35-e36. [PMID: 32035018 DOI: 10.1016/s0140-6736(20)30305-6] [Cited by in Crossref: 204] [Cited by in F6Publishing: 152] [Article Influence: 102.0] [Reference Citation Analysis]
37 Farhat Ullah M, Ali Y, Ramzan Khan M, Ullah Khan I, Yan B, Ijaz Khan M, Malik MY. A review of COVID-19: Treatment Strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. Saudi J Biol Sci 2021. [PMID: 34658640 DOI: 10.1016/j.sjbs.2021.10.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis. 2020;221:1688-1698. [PMID: 31822885 DOI: 10.1093/infdis/jiz656] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 56.0] [Reference Citation Analysis]
39 Signer J, Jonsdottir HR, Albrich WC, Strasser M, Züst R, Ryter S, Ackermann-Gäumann R, Lenz N, Siegrist D, Suter A, Schoop R, Engler OB. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol J 2020;17:136. [PMID: 32907596 DOI: 10.1186/s12985-020-01401-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
40 Wang L, Zhu Q, Xiang K, Zhang Y, Li B, Yu X, Yang G, Liang C, Yun H, Zhang M, Qin N, Gao L. Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor. Antimicrob Agents Chemother 2021;65:e02576-20. [PMID: 33782012 DOI: 10.1128/AAC.02576-20] [Reference Citation Analysis]
41 Göktaş F, Özbil M, Cesur N, Vanderlinden E, Naesens L, Cesur Z. Novel N ‐(1‐thia‐4‐azaspiro[4.5]decan‐4‐yl)carboxamide derivatives as potent and selective influenza virus fusion inhibitors. Arch Pharm Chem Life Sci 2019;352:1900028. [DOI: 10.1002/ardp.201900028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
42 Hayden FG, Whitley RJ. Respiratory Syncytial Virus Antivirals: Problems and Progress. The Journal of Infectious Diseases 2020;222:1417-21. [DOI: 10.1093/infdis/jiaa029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
43 Boyoglu-Barnum S, Tripp RA. Up-to-date role of biologics in the management of respiratory syncytial virus. Expert Opin Biol Ther 2020;20:1073-82. [PMID: 32264720 DOI: 10.1080/14712598.2020.1753696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
44 Shi HY, Zhu X, Li WL, Mak JWY, Wong SH, Zhu ST, Guo SL, Chan FKL, Zhang ST, Ng SC. Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies. Eur J Nutr 2021;60:4151-74. [PMID: 33852069 DOI: 10.1007/s00394-021-02519-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
45 Chang WT, Liu PY, Gao ZH, Lee SW, Lee WK, Wu SN. Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I K(M) or I K(DR) and in the Stimulation of I MEP. Front Pharmacol 2020;11:1091. [PMID: 32792942 DOI: 10.3389/fphar.2020.01091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
46 Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020;46:854-87. [PMID: 32222812 DOI: 10.1007/s00134-020-06022-5] [Cited by in Crossref: 670] [Cited by in F6Publishing: 687] [Article Influence: 335.0] [Reference Citation Analysis]
47 Sloan SE, Szretter KJ, Sundaresh B, Narayan KM, Smith PF, Skurnik D, Bedard S, Trevejo JM, Oldach D, Shriver Z. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. Antiviral Res 2020;184:104763. [PMID: 32151645 DOI: 10.1016/j.antiviral.2020.104763] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Zhang Y, Wang Y, Zhao J, Xiong Z, Fan Y, Zhang W, Zou X, Wang C, Han J, Li B, Lu B, Cao B; CAP-China Network. Severity and mortality of respiratory syncytial virus vs influenza A infection in hospitalized adults in China. Influenza Other Respir Viruses 2020;14:483-90. [PMID: 32449300 DOI: 10.1111/irv.12754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Francesconi V, Cichero E, Schenone S, Naesens L, Tonelli M. Synthesis and Biological Evaluation of Novel (thio)semicarbazone-Based Benzimidazoles as Antiviral Agents against Human Respiratory Viruses. Molecules 2020;25:E1487. [PMID: 32218301 DOI: 10.3390/molecules25071487] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
50 Bergeron HC, Tripp RA. Emerging small and large molecule therapeutics for respiratory syncytial virus. Expert Opin Investig Drugs 2020;29:285-94. [PMID: 32096420 DOI: 10.1080/13543784.2020.1735349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Rhodin MHJ, McAllister NV, Castillo J, Noton SL, Fearns R, Kim IJ, Yu J, Blaisdell TP, Panarese J, Shook BC, Or YS, Goodwin B, Lin K. EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog 2021;17:e1009428. [PMID: 33720995 DOI: 10.1371/journal.ppat.1009428] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
52 Lim JJ, Nilsson AC, Silverman M, Assy N, Kulkarni P, McBride JM, Deng R, Li C, Yang X, Nguyen A, Horn P, Maia M, Castro A, Peck MC, Galanter J, Chu T, Newton EM, Tavel JA. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. Antimicrob Agents Chemother 2020;64:e00352-20. [PMID: 32393496 DOI: 10.1128/AAC.00352-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
53 Pillet S, Gueudin M, Plantier JC, Vabret A. [Virological diagnosis of lower respiratory tract infections]. Rev Mal Respir 2021;38:58-73. [PMID: 33461842 DOI: 10.1016/j.rmr.2020.11.002] [Reference Citation Analysis]
54 Sims AC, Mitchell HD, Gralinski LE, Kyle JE, Burnum-Johnson KE, Lam M, Fulcher ML, West A, Smith RD, Randell SH, Metz TO, Sheahan TP, Waters KM, Baric RS. Unfolded Protein Response Inhibition Reduces Middle East Respiratory Syndrome Coronavirus-Induced Acute Lung Injury. mBio 2021;12:e0157221. [PMID: 34372702 DOI: 10.1128/mBio.01572-21] [Reference Citation Analysis]
55 Shahrajabian MH, Sun W, Cheng Q. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Hum Vaccin Immunother 2021;17:62-83. [PMID: 32783700 DOI: 10.1080/21645515.2020.1797369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
56 Memish ZA, Perlman S, Van Kerkhove MD, Zumla A. Middle East respiratory syndrome. Lancet 2020;395:1063-77. [PMID: 32145185 DOI: 10.1016/S0140-6736(19)33221-0] [Cited by in Crossref: 184] [Cited by in F6Publishing: 116] [Article Influence: 92.0] [Reference Citation Analysis]
57 Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med 2020;48:e440-69. [PMID: 32224769 DOI: 10.1097/CCM.0000000000004363] [Cited by in Crossref: 441] [Cited by in F6Publishing: 250] [Article Influence: 220.5] [Reference Citation Analysis]
58 Sekharan S, Liu X, Yang Z, Liu X, Deng L, Ruan S, Abramov Y, Sun G, Li S, Zhou T, Shi B, Zeng Q, Zeng Q, Chang C, Jin Y, Shi X. Selecting a stable solid form of remdesivir using microcrystal electron diffraction and crystal structure prediction. RSC Adv 2021;11:17408-12. [PMID: 35479679 DOI: 10.1039/d1ra03100g] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. [DOI: 10.1136/bmj.l5021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
60 Marathe BM, Asthagiri Arunkumar G, Vogel P, Pascua PNQ, Jones J, Webby RJ, Krammer F, Govorkova EA. Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus. Antimicrob Agents Chemother 2020;64:e00284-20. [PMID: 32631823 DOI: 10.1128/AAC.00284-20] [Reference Citation Analysis]
61 Zarubaev VV, Garshinina AV, Volobueva AS, Slita AV, Yarovaya OI, Bykov VV, Leonov KA, Motov VS, Khazanov VA, Salakhutdinov NF. Optimization of application schedule of camphecene, a novel anti-influenza compound, based on its pharmacokinetic characteristics. Fundam Clin Pharmacol 2022;36:518-25. [PMID: 34984730 DOI: 10.1111/fcp.12750] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med 2020;46:315-28. [PMID: 32040667 DOI: 10.1007/s00134-020-05943-5] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 52.0] [Reference Citation Analysis]
63 Nadeem MS, Zamzami MA, Choudhry H, Murtaza BN, Kazmi I, Ahmad H, Shakoori AR. Origin, Potential therapeutic targets and treatment for coronavirus disease (COVID-19). Pathogens. 2020;9. [PMID: 32331255 DOI: 10.3390/pathogens9040307] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 16.0] [Reference Citation Analysis]
64 Andrade BS, Rangel FS, Santos NO, Freitas ADS, Soares WRA, Siqueira S, Barh D, Góes-Neto A, Birbrair A, Azevedo VAC. Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. Front Pharmacol 2020;11:590598. [PMID: 33390967 DOI: 10.3389/fphar.2020.590598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
65 Guo-Parke H, Linden D, Weldon S, Kidney JC, Taggart CC. Mechanisms of Virus-Induced Airway Immunity Dysfunction in the Pathogenesis of COPD Disease, Progression, and Exacerbation. Front Immunol 2020;11:1205. [PMID: 32655557 DOI: 10.3389/fimmu.2020.01205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
66 Kumar SU, Priya NM, Nithya SR, Kannan P, Jain N, Kumar DT, Magesh R, Younes S, Zayed H, Doss CGP. A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. 3 Biotech 2021;11:198. [PMID: 33816047 DOI: 10.1007/s13205-021-02749-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
67 Zabolotskikh I, Kirov M, Lebedinskii K, Protsenko D, Avdeev S, Andreenko A, Arsentyev L, Afonchikov V, Afukov I, Belkin A, Boeva E, Bulanov A, Vasiliev Y, Vlasenko A, Gorbachev V, Grigor'ev E, Grigor'ev S, Gritsan A, Eremenko A, Ershov E, Zamyatin M, Kuzovlev A, Kulikov A, Lakhin R, Leiderman I, Lenkin A, Mazurok V, Musaeva T, Nikolaenko E, Orlov Y, Petrikov S, Roitman E, Ronenson A, Smetkin A, Sokolov A, Stepanenko S, Subbotin V, Ushakova N, Khoronenko V, Tsarenko S, Shifman E, Shukevich D, Shchegolev A, Yaroshetskiy A, Yarustovsky M. Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. Annals of Critical Care. Annals of critical care 2020. [DOI: 10.21320/1818-474x-2020-s1-9-120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
68 Noori R, Sardar M. An outlook on potential protein targets of COVID-19 as a druggable site. Mol Biol Rep 2022. [PMID: 35790657 DOI: 10.1007/s11033-022-07724-3] [Reference Citation Analysis]
69 Pecetta S, Finco O, Seubert A. Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. Semin Immunol 2020;50:101427. [PMID: 33277154 DOI: 10.1016/j.smim.2020.101427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
70 [DOI: 10.1101/2020.04.03.024257] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
71 Kabir MT, Uddin MS, Hossain MF, Abdulhakim JA, Alam MA, Ashraf GM, Bungau SG, Bin-Jumah MN, Abdel-Daim MM, Aleya L. nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. Front Cell Dev Biol 2020;8:616. [PMID: 32754599 DOI: 10.3389/fcell.2020.00616] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
72 Zhao Q, Zhang L, Zhang S, Gao X, Li Y, Chen M, Gao X, Liu M. Benefits from Shortening Viral Shedding by Traditional Chinese Medicine Treatment for Moderate COVID-19: An Observational Study. Evid Based Complement Alternat Med 2022;2022:7179050. [PMID: 35154352 DOI: 10.1155/2022/7179050] [Reference Citation Analysis]
73 Rakedzon S, Neuberger A, Domb AJ, Petersiel N, Schwartz E. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? J Travel Med 2021;28:taab005. [PMID: 33480414 DOI: 10.1093/jtm/taab005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
74 Cai W, Wen H, Zhou Q, Wu L, Chen Y, Zhou H, Jin M. 14-Deoxy-11,12-didehydroandrographolide inhibits apoptosis in influenza A(H5N1) virus-infected human lung epithelial cells via the caspase-9-dependent intrinsic apoptotic pathway which contributes to its antiviral activity. Antiviral Res 2020;181:104885. [PMID: 32702348 DOI: 10.1016/j.antiviral.2020.104885] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
75 Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020;53:436-443. [PMID: 32307245 DOI: 10.1016/j.jmii.2020.03.034] [Cited by in Crossref: 218] [Cited by in F6Publishing: 180] [Article Influence: 109.0] [Reference Citation Analysis]
76 Tiwari V, Kumar M, Tiwari A, Sahoo BM, Singh S, Kumar S, Saharan R. Current trends in diagnosis and treatment strategies of COVID-19 infection. Environ Sci Pollut Res Int 2021;28:64987-5013. [PMID: 34601675 DOI: 10.1007/s11356-021-16715-z] [Reference Citation Analysis]
77 Sestili P, Stocchi V. Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19. Front Pharmacol 2020;11:854. [PMID: 32581809 DOI: 10.3389/fphar.2020.00854] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
78 Golamari R, Kapoor N, Devaraj T, Sahu N, Kramer C, Jain R. Experimental therapies under investigation for COVID-19. J Community Hosp Intern Med Perspect 2021;11:187-93. [PMID: 33889318 DOI: 10.1080/20009666.2021.1874093] [Reference Citation Analysis]
79 Massari S, Desantis J, Nizi MG, Cecchetti V, Tabarrini O. Inhibition of Influenza Virus Polymerase by Interfering with Its Protein-Protein Interactions. ACS Infect Dis 2021;7:1332-50. [PMID: 33044059 DOI: 10.1021/acsinfecdis.0c00552] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
80 Elawar F, Oraby AK, Kieser Q, Jensen LD, Culp T, West FG, Marchant DJ. Pharmacological targets and emerging treatments for respiratory syncytial virus bronchiolitis. Pharmacol Ther 2021;220:107712. [PMID: 33121940 DOI: 10.1016/j.pharmthera.2020.107712] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
81 Tian L, Qiang T, Liang C, Ren X, Jia M, Zhang J, Li J, Wan M, YuWen X, Li H, Cao W, Liu H. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. Eur J Med Chem 2021;213:113201. [PMID: 33524687 DOI: 10.1016/j.ejmech.2021.113201] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]